genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Phase I clinical trials (Clinical trial)
Bioprocessing
Biosimilar Manufacturer Focuses on Process Optimization
Cancer
Immunosuppressant Ruxolitinib Boosts Checkpoint Inhibitor Response in Patients with Hodgkin Lymphoma, Phase I Data Show
Cancer
FDA Imposes Partial Hold on BioNTech/MedLink ADC Trial after Three Patient Deaths
Drug Discovery
Evolving Trends in Pharmaceuticals
Infectious Diseases
HIV Vaccine Triggered Elusive Broadly Neutralizing HIV Antibodies, Trial Shows
Bioprocessing
Getting the Economical Edge on Cheaper Cell Therapy Manufacturing
Cancer
AACR: Colon Cancer Patients Respond to Antibody/KRAS Inhibitor Combo
News
Stem Cell Therapy For Spinal Cord Injury Advances with Positive Phase I Results
Cancer
CAR T Cells Target Two Proteins, Shrink Brain Tumors in Phase I Trial
Bioprocessing
Domain Therapeutics and Chime Biologics Ink Cancer Immunotherapy Agreement
1
2
3
...
10
Page 1 of 10
Scroll Up
Scroll Up
